Posted by Michael Wonder on 26 Feb 2025
Odronextamab BLA accepted for FDA review for the treatment of relapsed/refractory follicular lymphoma
26 February 2025 - FDA decision expected by 30 July 2025.
Regeneron Pharmaceuticals today announced that the US FDA has accepted for review the resubmission of the biologics license application for odronextamab in relapsed/refractory follicular lymphoma after two or more lines of systemic therapy.
